[Renaissance of immuno-oncology for urological tumors : Current status].
With the advent of immune checkpoint inhibitors, immunotherapy has gained new importance in oncology. Current research is focused on the cytotoxic T‑lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) immune checkpoints. The CTLA4 antibody ipilimumab (melanoma) as well as the PD-1 antibodies nivolumab (melanoma, non-small cell lung cancer and renal cell carcinoma) and pembrolizumab (melanoma) are approved for the treatment of metastatic disease in Europe. Immune checkpoint inhibitors (re)activate the immune system against cancer cells and appear to be more effective than current standards for many tumors. The toxicity profile is favorable but involves new so-called immune-related side effects, which need to be recognized and treated in time. Immune checkpoint inhibitors are also currently being tested in uro-oncology in phase 3 trials relevant for approval status. Based on this it is to be expected that immune checkpoint inhibitors will become a new standard (as monotherapy or as part of combination therapy) in the early lines of therapy in the near future and replace the previous standard therapies, particularly for metastasized renal cell carcinoma and urothelial cancer.
Urologische Klinik und Poliklinik, Universitätsklinikum Jena, Lessingstraße 1, 07749, Jena, Deutschland. marc-oliver.grimm@med.uni-jena.de.
M-O
MO
Grimm
Urologische Klinik und Poliklinik, Universitätsklinikum Jena, Lessingstraße 1, 07749, Jena, Deutschland.
Y
Y
Winkler
Urologische Klinik und Poliklinik, Universitätsklinikum Jena, Lessingstraße 1, 07749, Jena, Deutschland.
I
I
Fetter
Urologische Klinik und Poliklinik, Universitätsklinikum Jena, Lessingstraße 1, 07749, Jena, Deutschland.
H
H
Oppel-Heuchel
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab; D009367:Neoplasm Staging; D000077594:Nivolumab; D014571:Urologic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074324:Ipilimumab; D000077594:Nivolumab; C582435:pembrolizumab
CTLA4 inhibitor; Immune checkpoint inhibitor; Immunotherapy; Nivolumab; PD-1 inhibitor; PD-L1 inhibitor